A recent study published in The New England Journal of Medicine has found that the use of semaglutide, a drug commonly used to treat type 2 diabetes and obesity, may also provide relief from severe knee pain associated with osteoarthritis. The study enrolled 407 patients with an average BMI classified as obese and diagnosed with moderate to severe knee pain. Over the course of the 68-week study, those using semaglutide lost an average of 13.7% of their body weight and experienced a significant reduction in their pain scores compared to those who did not use the drug.
Experts believe that the weight loss induced by semaglutide plays a significant role in reducing knee pain by alleviating the strain on joints. In addition to weight loss, semaglutide is also known to balance blood sugar levels and reduce inflammation, both of which may contribute to pain relief in osteoarthritis patients. Sandeep Singh, MS, MBBS, an orthopedic surgeon, explains that every pound of weight lost takes about four pounds of pressure off the knee joints, leading to considerable relief. Singh also notes that the anti-inflammatory effects of GLP-1 receptor agonists like semaglutide may further contribute to pain relief beyond weight loss alone.
Experts are optimistic about the future of drugs like semaglutide and believe that continued advancements in GLP-1 receptor agonists may lead to further improvements in overall health and quality of life for patients with osteoarthritis and other conditions. The evolution from semaglutide to dual and triple agonists represents a significant progression in enhancing cellular efficiencies and optimizing therapeutic outcomes. As research in this area continues to progress, we may see more life-changing results from drugs like semaglutide in the future.